MDS expands Taiwan capacity in early stage focus

By Nick Taylor

- Last updated on GMT

Related tags: Mds pharma services, Pharmacokinetics, Pharmacology, Drug discovery

MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.

The overhaul is part of MDS’ increased focus on early stage research, which was demonstrated by the sale of its late stage trial unit to INC research, and is due to be completed in 2010.

MDS’ expansion will double the site’s in vivo ​safety and efficacy testing capacity, with space tailored to an individual client’s needs, and upgrade and expand its molecular screening and profiling services.

This includes the installation of additional robotic high-throughput screening capacity and analytical support, which MDS believes will improve the site’s automated molecular screening and profiling capability and efficiency.

David Spaight, president of MDS Pharma Services, said: "This new and expanded facility will cement our position as the global leader in the discovery pharmacology space, where we are one of the top two providers of molecular screening, and a key supplier of in vivo efficacy and safety testing​.

"This investment builds on a 40-year track record of success in this service area, and supports our recently announced strategic focus on the discovery through Phase IIa proof-of-concept segment of the outsourcing market​."

Early-stage offering

The Taiwan facility forms part of MDS’ Pharmacology/DMPK (drug metabolism and pharmacokinetics) services, which offers molecular, cellular, ADME (absorption, distribution, metabolism, and excretion) and in vivo​ assays.

Clients can use these services to help identify drug candidates, profile for selectivity, assess potential for adverse events, evaluate efficacy and establish proof of concept.

MDS believes that clients using these services can “help speed lead optimization earlier in the discovery phase and streamline the surest path to the clinic​”.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars